Oberic, L., Viret, F., Baey, C., Ychou, M., Bennouna, J., Adenis, A., . . . Ducreux, M. (2011). Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: A FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. BioMed Central.
Chicago-stil citatOberic, Lucie, et al. Docetaxel- and 5-FU-concurrent Radiotherapy in Patients Presenting Unresectable Locally Advanced Pancreatic Cancer: A FNCLCC-ACCORD/0201 Randomized Phase II Trial's Pre-planned Analysis and Case Report of a 5.5-year Disease-free Survival. BioMed Central, 2011.
MLA-referensOberic, Lucie, et al. Docetaxel- and 5-FU-concurrent Radiotherapy in Patients Presenting Unresectable Locally Advanced Pancreatic Cancer: A FNCLCC-ACCORD/0201 Randomized Phase II Trial's Pre-planned Analysis and Case Report of a 5.5-year Disease-free Survival. BioMed Central, 2011.